Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

54.32 -1.45 (-2.60%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
65 66 Next >
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant... 
Via Benzinga
Exposures Product Safety
Bonds Break Down And Send Everyone To Cash
This situation is where the danger, the opportunity, and the action are right now. 
Via Talk Markets
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
From Bristol Myers Squibb
Via Business Wire
(BMY) - Analyzing Bristol-Myers Squibb's Short Interest
Via Benzinga
This Unpopular Dividend Stock Is a Buy
This top pharma stock has fallen too far. 
Via The Motley Fool
Spotlight on Bristol-Myers Squibb: Analyzing the Surge in Options Activity
Via Benzinga
Is Bristol Myers' Dividend in Danger?
Should investors brace for a dividend cut? 
Via The Motley Fool
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
From Bristol Myers Squibb
Via Business Wire
Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M
A Hawaii judge has ordered Bristol Myers Squibb and Sanofi to pay $916 million for not warning non-white patients about the health risks of their blood thinner Plavix. The ruling follows a previous... 
Via Benzinga
Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
From Bristol Myers Squibb
Via Business Wire
2 Beaten-Down Stocks to Buy and Hold for 10 Years
They offer plenty of upside and solid dividend growth. 
Via The Motley Fool
Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign
From Bristol Myers Squibb
Via Business Wire
1 Stock I Wouldn't Touch With a 10-Foot Pole
This stock isn't as safe as it seems, and now isn't the time to dabble. 
Via The Motley Fool
3 Bargain Stocks to Buy Now: May 2024
These bargain stocks to buy provide substantial upside since they are trading at a significant discount to their historical multiples. 
Via InvestorPlace
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
From Bristol Myers Squibb
Via Business Wire
Large Cap Biopharmaceuticals Performance
The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​. 
Via Talk Markets
Insider Trading is Good News for These Stocks
Insiders are buying these hot stocks that have ample upside for investors. The list includes pharma, entertainment, and financial stocks and Berkshire buys. 
Via MarketBeat
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine,... 
Via Benzinga
Walmart Earnings And The State Of The Consumer
​​​​​​​This earnings season showed a notable acceleration in the earnings growth pace, which produces a reassuring earnings backdrop for the market. 
Via Talk Markets
FDA Approves Expanded Use Of Bristol Myers Squibb's Breyanzi Cancer Cell Therapy For Previously Treated Follicular Lymphoma
FDA grants accelerated approval for Bristol Myers Squibb's Breyanzi, a CAR T cell therapy, for relapsed or refractory follicular lymphoma. Breyanzi is included in NCCN guidelines and shows high... 
Via Benzinga
Exposures Product Safety
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
From Bristol Myers Squibb
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Dividend Capture Captains: The 3 Best Blue-Chip Stocks for Tactical Traders
Using these capture-the-dividend stock strategy for tactical traders can be profitable with high-yield blue-chips. 
Via InvestorPlace
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day
The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM. 
Via Investor's Business Daily
Down but Not Out: 3 Stocks to Buy on a Post-Earnings Dip
Bad news can be good news for an enterprising investor with a longer time horizon than the market's immediate reaction. 
Via The Motley Fool
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
From Bristol Myers Squibb
Via Business Wire
Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore
The sudden divergence has made clear some laggards who have ultra-low RSI readings that might just be too good to ignore. Here are 3 worth watching closely. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
What's Going On With Medical Therapeutic Firm Aethlon Medical On Friday?
Aethlon Medical unveils results in removing extracellular vesicles (EVs) from plasma. Preclinical evidence supports upcoming phase 1 trials for solid tumor patients undergoing anti-PD-1 monotherapy. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.